Compare Gilead Sciences, Inc. (GILD) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Icl Group Ltd — how do they compare? Gilead Sciences, Inc. trades at $132.98 (market cap $163.51B), while Icl Group Ltd trades at $5.06 (market cap $6.57B). The key difference: Gilead Sciences, Inc. is far larger — about 24.9× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.74%). Which is the better fit depends on your goals.
| GILD | ICL | |
|---|---|---|
Market Cap | $163.51B | $6.57B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $7.03 |
52-Week Low | $108.22 | $4.80 |
Enterprise Value | $178.05B | $9.14B |
Dividend Yield | 2.49% | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
ICL trades at $5.01, up 1.62% with bearish technical signals despite recent earnings beats. The company maintains stable cash flow with $1.06B from operations in 2025, though revenue has declined from $10B in 2022 to $7.15B in 2025. Recent $800M senior notes offering strengthens liquidity while analyst sentiment remains cautious with 100% hold ratings.
ICL faces margin compression with net income margin dropping to 3.52% amid rising costs. The stock's 24.29 P/E suggests full valuation relative to earnings growth. Key risks include raw material inflation and foreign exchange volatility, though improved debt management provides financial stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
